SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

JUAN SOLIVERA VELAANTONIO CARLOS FUENTES FAYOSJUSTO PASTOR CASTAÑO FUENTESJUAN MANUEL JIMÉNEZ VACASRAUL MIGUEL LUQUE HUERTASJESÚS MIGUEL PÉREZ GÓMEZMANUEL DAVID GAHETE ORTIZ2026-01-292026-01-29202210.1186/s13046-022-02241-42-s2.0-85123796007https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/34544Cancer ResearchOncologySF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalancesresearch article